XTL Biopharmaceuticals has shuttered the development program for XTL-2125 after it failed to demonstrate efficacy in a Phase I trial for hepatitis C. Viral load reductions proved negligible in ...
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced the ...
XTL could receive $104 million upon certain development and commercialization successes. XTL Biopharmaceuticals could make up to $108 million through a licensing deal with Presidio Pharmaceuticals ...
March 20 (Reuters) - XTL Biopharmaceuticals Ltd said it signed a $108 million deal licensing its pre- clinical hepatitis C program to San-Francisco based private biotechnology firm Presidio ...
March 20 (Reuters) - XTL Biopharmaceuticals Ltd said it signed a $108 million deal licensing its pre- clinical program in hepatitis C to San-Francisco based private biotechnology firm Presidio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results